The collapse of FTX and the fraud conviction of Theranos founder Elizabeth Holmes represent two of the most spectacular failures of due diligence in modern financial history. In both cases, sophisticated investors — venture capital firms, hedge funds, and institutional allocators — committed billions of dollars based on narratives that crumbled under scrutiny. The question is not whether these investors were careless, but whether the traditional diligence framework was ever equipped to catch these red flags in the first place.
Traditional commercial due diligence relies heavily on management interviews, expert networks, and qualitative market assessments. These methods are valuable, but they share a critical weakness: they are fundamentally dependent on the honesty of the people being evaluated. Theranos presented fabricated lab results and staged demonstrations. FTX obscured the relationship between its exchange and Alameda Research behind layers of corporate complexity. In both cases, the qualitative signals — charismatic founders, impressive boards, rapid revenue growth — overwhelmed the quantitative warning signs.
A data-driven approach to diligence would have surfaced anomalies that narrative-based analysis missed. For Theranos, statistical analysis of published clinical accuracy claims against peer-reviewed benchmarks would have revealed that their reported error rates were biologically implausible. For FTX, on-chain analysis of token flows between FTX and Alameda, combined with balance sheet reconciliation against publicly observable exchange reserves, would have flagged the liquidity mismatch months before the collapse. These are not hypothetical techniques — they are standard tools in quantitative diligence that were simply not applied.
The lesson for PE and VC firms is not that traditional diligence should be abandoned, but that it must be augmented. Data science brings hypothesis testing, anomaly detection, and independent verification to a process that has historically relied on trust. When the stakes are measured in billions, the cost of adding statistical rigor to your diligence process is negligible compared to the cost of missing a fraud. The firms that survive the next cycle will be the ones that treat data not as a supplement to diligence, but as its foundation.